Physician profile
Anmarie Moore
NPI 1174734297
$3,336.58
in general payments reported to CMS, 2019-2025
19 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $131 · 2021: $272 · 2022: $545 · 2023: $505 · 2024: $531 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.35 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,442.82 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $449.83 | 2019-2022 | |
| Gilead Sciences, INC. | $263.50 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.77 | 2020-2025 | Entyvio |
| Lilly USA, LLC | $197.81 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $175.04 | 2019-2025 | Tremfya |
| Aimmune Therapeutics, INC. | $115.87 | 2025 | Zenpep, Vowst |
| Celgene Corporation | $109.43 | 2021-2023 | Zeposia |
| Boston Scientific Corporation | $70.09 | 2019-2023 | Interject |
| Pfizer INC. | $66.19 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $47.57 | 2022-2025 | |
| Madrigal Pharmaceuticals | $40.74 | 2025 | Rezdiffra |
| Ucb, INC. | $30.71 | 2019 | |
| Ardelyx, INC. | $30.71 | 2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $23.97 | 2024 | Iqirvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $20.56 | 2024 | Heplisav-B |
| Ironwood Pharmaceuticals, INC | $19.68 | 2020 | |
| Allergan, INC. | $13.51 | 2019 | |
| Ethicon US, LLC | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anmarie Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.